A Case Report on Mephentermine Induced Psychosis with Acute Liver & Kidney Injury
Abstract
Background: Mephentermine is a sympathomimetic agent derived
from methamphetamine. It is a commonly used drug for the treatment
of hypotension during anaesthesia. Its abuse has markedly increased
especially in the young population due to its stimulant properties and
ability to boost performance in competitive sports or bodybuilding. Very
few cases of Mephentermine dependence with or without psychosis
have been reported from India and worldwide.
Case Description: A 24-year-old male presented with a sudden
onset of behavioural abnormalities a few hours following the use
of Mephentermine. He was very agitated and restless. On physical
examination, tachycardia, elevated BP and bilaterally dilated pupils were
found. His symptoms remitted within a few hours of using Injection
Haloperidol 10 mg with Lorazepam 4 mg once. He was found to have
grossly deranged liver and kidney function tests. There was no past
and family history of any psychiatric illness. No past history of any
physical illness.
Conclusion: No previous report of mephentermine induced psychosis
with acute kidney and liver injury has been reported in the literature.
Cases such as this may be common among the general public. Long
term follow-up is required to know the course and outcome in such
unusual cases.
How to cite this article:
Debnath M, Bhagabati D. A Case Report on
Mephentermine Induced Psychosis with Acute
Liver & Kidney Injury. Rec Adv Path Lab Med.
2021;7(1&2):4-6.
References
Singh P, Sidhu BS, Raj R, Mittal N. Mephentermine dependence: emerging trend of substance abuse and its challenges. Int J Med Dent Sci. 2019;8(1):1715-7. [Google Scholar]
Sawant NS, Vispute CD. Mephentermine dependence with induced psychosis. German J Psychiatry. 2012;15(2):69-71. [Google Scholar]
Basu D, Nebhinani N. Mephentermine dependence without psychosis. Indian J Med Sci. 2009 Mar;63(3). [PubMed] [Google Scholar]
Gupta KK, Singh A, Singh G, Aggarwal S. Uncommon drug abuse: an anaesthetist dilemma. Anesth Essays Res. 2015;9(1):116-7. [PubMed] [Google Scholar]
de Sousa HF, de Oliveira MF, Lima MD, De Oliveira JR. Mephentermine dependence without psychosis: a Brazilian case report. Addiction. 2010;105(6):1129-30. [PubMed] [Google Scholar]
Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. 2008;154(3):606-22. [PubMed] [Google Scholar]
Oliveira MF, de Sousa HF, Lima MC, de Oliveira JR. Mephentermine: rediscovering its biology and use, misuse and their implications. Braz J Psychiatry. 2011;33(1):98-9. [PubMed] [Google Scholar]
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Open Access
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
